Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms
On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review
Article first published online: 29 SEP 2011
© 2011 The Author(s)/Acta Pædiatrica © 2011 Foundation Acta Pædiatrica
Volume 100, Issue 12, pages 1523–1527, December 2011
How to Cite
Hård, A.-L. and Hellström, A. (2011), On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review. Acta Paediatrica, 100: 1523–1527. doi: 10.1111/j.1651-2227.2011.02445.x
- Issue published online: 8 NOV 2011
- Article first published online: 29 SEP 2011
- Accepted manuscript online: 20 AUG 2011 06:29AM EST
- Received 16 June 2011; revised 13 August 2011; accepted 16 August 2011.
- Anti-vascular endothelial growth factor;
- Retinopathy of prematurity
Off-label intravitreal use of the vascular endothelial growth factor (VEGF) antibody bevacizumab for retinopathy of prematurity (ROP) increases despite lack of studies on safety, pharmacokinetics and dosage in developing individuals. Systemic absorption has been considered negligible. A literature search was performed with emphasis on potential adverse systemic effects in developing individuals.
Conclusion: Intravitreal bevacizumab enters the general circulation, suppresses plasma VEGF levels and remains in the blood for more than 8 weeks in primates. Possible adverse effects on VEGF-dependent development must be considered.